Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular Carcinoma HCC Liver cancer Child Pugh A HCC Stage C
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 162
Healthy volunteers: no

Brief summary:
The purpose of this open-label, randomized, phase II study is to compare the safety and efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with advanced Hepatocellular Carcinoma (HCC). This trial will be opened in countries of the Asia-Pacific region.

Detailed description:

Arms:
arm 1: capsule arm 2: tablet

Interventions: intervention 1: dovitinib intervention 2: sorafenib
Intervention descriptions: intervention 1: 500 mg p.o. o.d. 5 days on/2 days off intervention 2: 400 mg p.o. b.i.d.

Protocol document: